A Phase 2 Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
A Phase 2 Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1/PD-1 immunotherapy agent. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior treatment regimens. This study is intended to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment and to evaluate the efficacy, safety, and pharmacokinetics of alisertib.
Inclusion Criteria:
Exclusion Criteria:
Note: There are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.
ClinicalTrials@pumabiotechnology.com(424) 248-6500
Washington D.C., District of Columbia 20057, United States
Fort Lauderdale, Florida 33316, United States
Indianapolis, Indiana 46202, United States
Baltimore, Maryland 21201, United States
Charleston, South Carolina 29425, United States
Blacksburg, Virginia 24073, United States